Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Treatment-seeking adults with moderate to severe alcohol use disorder (DSM-5 criteria) and BMI 30 received either once-weekly subcutaneous semaglutide titrated to 2.4 mg or saline placebo, both for 26 weeks
A mismatch between glycerol and fatty-acid release may therefore reflect fatty-acid handling rather than an analytical error
National Poison Prevention Week (in the United States) is March 16-22, 2025
When to contact your healthcare provider Contact your healthcare provider right away if you have: severe or persistent side effects vomiting that does not stop severe stomach pain trouble breathing swelling of the face or throat signs of dehydration yellowing of the skin or eyes confusion or fainting vision changes References Wegovy (semaglutide) prescribing information
